Isopropyl Ester Cooling Agents for Non-Keratinized Tissue Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current topical anti-nociceptive compounds have limited efficacy on sensory discomfort from non-keratinized stratified epithelial tissues, such as ocular surfaces, and often cause irritancy or toxicity, necessitating a new class of pharmacological agents that can effectively suppress discomfort without these drawbacks.
Innovation Solution
Development of Isopropyl Ester Compounds, specifically [((1R,2S,5R)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-acetic acid isopropyl ester and its derivatives, which act as potent and long-acting cooling agents selectively on non-keratinized epithelial tissues, providing relief without irritancy or toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current topical anti-nociceptive compounds are used, then sensory discomfort is suppressed, but irritancy and toxicity occur
Solution Approach 1:
The patent modifies the chemical structure of traditional menthol compounds by converting the carboxylic acid group to an isopropyl ester, creating compounds with altered pharmacological properties. This structural parameter change results in compounds that maintain cooling and analgesic effects while reducing irritancy and toxicity, particularly on non-keratinized stratified epithelial tissues
Solution Approach 2:
The invention creates composite chemical structures by combining the menthol core structure with glycine isopropyl ester moieties, forming N-substituted p-menthane carboxamides and related compounds. This composite approach yields compounds with improved safety profiles while maintaining therapeutic efficacy
2Reliability
If topical anti-nociceptive compounds are applied to non-keratinized stratified epithelial tissues, then sensory discomfort is alleviated, but the duration of action is limited
Solution Approach 1:
The isopropyl ester modification of the carboxylic acid group fundamentally changes the pharmacokinetic properties of the compound, extending its duration of action on non-keratinized stratified epithelial tissues from minutes to several hours, while maintaining potent cooling and analgesic effects
3Temperature
If cooling agents are applied to keratinized epithelial tissues, then cooling effect is achieved, but selectivity for non-keratinized tissues is lost
Solution Approach 1:
The patent describes compounds that exhibit differential effects on different tissue types: potent cooling and analgesic effects on non-keratinized stratified epithelial tissues, while having minimal or no effect on keratinized epithelial tissues. This local quality selectivity is achieved through the specific isopropyl ester chemical structure
Solution Approach 2:
The chemical modification to isopropyl esters creates compounds with altered tissue selectivity parameters, enabling preferential action on non-keratinized stratified epithelial tissues while sparing keratinized tissues, thus achieving targeted therapy with reduced off-target effects
Data Source
AI summary
The present invention pertains generally to the field of coolants and medical therapy. More particularly, the present invention relates to certain anti-nociceptive agents, such as [((1R,2S,5R)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-acetic acid isopropyl ester, that are potent and long-acting and selectively cooling for non-keratinized epithelial tissues as compared to keratinized epithelial tissues, and are useful, for example, for the treatment of (e.g., the alleviation of symptoms of; the amelioration of) sensory discomfort of non-keratinized stratified epithelial (NKSE) tissue; and so for treatment of: sensory discomfort of an ocular surface, an eyelid, a margin of an eyelid, an anterior part of an eyeball, a conjunctiva, a lachrymal system, a pre-corneal film, or a cornea, a lining of the oral cavity, an internal portion of the lips, a pharyngeal surface, an esophageal surface, or an anogenital surface; eye discomfort, e.g., caused by extended wear of contact lenses, by eye strain and/or fatigue, by air pollutants, by excessive exposure to the sun, by conjunctivitis, by dry eye syndrome; sensory discomfort associated with oral mucositis; airway (e.g., larynx, trachea, and/or bronchi) tightness, discomfort in the airways (e.g., larynx, trachea, and/or bronchi), choking, cough, and/or dyspnea, e.g., associated with asthma and/or chronic obstructive pulmonary diseases (COPD).